BCP Customer Partnership Meeting

The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on Tuesday, April 26, 2016 at the USPTO Headquarters (Alexandria, VA).  The agenda for the meeting is as follows:

• Welcoming and Opening Remarks (10:00 - 10:10 am EST) -- Mark Powell, Deputy Commissioner, International Patent Cooperation, USPTO; Jerry Lorengo Director, TC1600, USPTO; Daniel Sullivan Director, TC1600, USPTO; and Wanda Walker Director, TC1600, USPTO

• International Patent Cooperation Featuring Global Dossier (10:10 - 11:00 am) -- Jessica Patterson, Program Manager, International Patent Cooperation

• Outside Perspectives on International Patent Cooperation (11:00 - 11:25 am) -- Anthony P. Venturino, Vorys, Sater, Seymour and Pease LLP

• Break (11:25 - 11:30 am)

• Supplemental Examination (11:30 am - 12:30 pm) -- Jean Witz, SPE, Central Reexamine Art Unit, USPTO

• Lunch (12:30 - 1:30 pm)

• Third Party Submission (1:00 - 2:00 pm EDT) -- Bennett Celsa, Quality Assurance Specialist, TC1600, USPTO (Alexandria)

• Antibody Written Description (1:30 - 2:30 pm) -- Joanne Hama, SPE, TC1600, USPTO

• Break (2:30 - 2:40 pm)

• Enhancing the Quality of Biologics Patents: Computational Simulations as Evidence (2:40 - 3:40 pm) -- Brian Lathrop, Law Office of Brian K. Lathrop

• Closing Remarks (3:40 - 3:50 pm) – Directors, TC1600, USPTO

The meeting can be viewed online here.  Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting, can be found here.

Comments

[Clark]

I found the combination of Joanne Hama's and Brian Lathrop's talks to be discouraging in that they seem to be suggesting that the PTO will soon be taking an even more restrictive view of sequence-based claims and antibody claims. Did anybody else think the outlook for such claims is now bleaker than it was the day before?